prof. dr. J.G.J. (Jan) van de Winkel
Full Professor
- Laboratory for Translational Immunology (LTI)
Contact
Side Activities
Instelling
Functie
Tijdvak
Genmab
President & CEO (sinds 2010)
1999-heden
Hookipa Pharma Inc
Voorzitter, raad van commissarissen
2017-heden
LEO Pharma
Lid, raad van commissarissen
2017-heden
Celdara Medical
Lid, raad van commissarissen
2012-heden
Thuja Capital Healthcare Fund
Lid, wetenschappelijke adviesraad
2006-heden
Capricorn Health-tech Fund
Lid, adviesraad
2010-heden
Research Output (249)
Complement is activated by IgG hexamers assembled at the cell surface.
Diebolder C.A., Beurskens F.J.M., de Jong R.N., Koning R.I., Strumane K., Lindorfer M.A., Voorhorst M.M., Ugurlar D., Rosati S, Heck A.J.R., van de Winkel J.G.J., Wilson I.A., Koster A.J., Taylor R.P., Saphire E.O., Burton D.R., Schuurman J., Gros P., Parren P.W.H.I. 2014, In: Science. 343 , p. 1260-1263 4 p.
The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells.
Glorius P., Baerenwaldt A., Kellner C., Staudinger M., Dechant M., Stauch M., Beurskens F.J., Parren P.W.H.I., van de Winkel J.G.J., Valerius T., Humpe A., Repp R., Gramatzki M., Nimmerjahn F., Peipp M. 2013, In: Leukemia. 27 , p. 190-201 12 p.
Staphylococcus aureus formyl peptide receptor-like 1 inhibitor (FLIPr) and its homologue FLIPr-like are potent FcγR antagonists that inhibit IgG-mediated effector functions
Stemerding A.M., Kohl J., Pandey M.K., Kuipers A., Leusen J.H.W., Boross P., Nederend M., Vidarsson G., Weersink A.J.L., van de Winkel J.G.J., van Kessel C.P.M., van Strijp J.A.G. 2013, In: Journal of Immunology. 191 , p. 353-362 10 p.
IgA EGFR antibodies mediate tumour killing in vivo.
Boross P., Lohse S., Nederend M., Jansen J.H.M., van Tetering G., Dechant M., Peipp M., Royle L., Liew L.P., Boon L, van Rooijen N., Bleeker W.K., Parren P., van de Winkel J.G.J., Valerius T., Leusen J.H.W. 2013, In: Embo Molecular Medicine. 5 , p. 1213-1216 4 p.
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.
Labrijn A.F., Meesters J., Goeij B.E., van den Bremer E.T.J., Neijssen J., van Kampen M.D., Strumane K., Verploegen S., Kundu A., Gramer M.J., van Berkel P.H.C., van de Winkel J.G.J., Schuurman J., Parren P.W.H.I. 2013, In: Proceedings of the National Academy of Sciences of the United States of America. 110 , p. 5145-5150 6 p.
Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.
Kellner C., Maurer T., Hallack D., Repp R., van de Winkel J.G.J., Parren P.W.H.I., Valerius T., Humpe A., Gramatzki M., Peipp M. 2012, In: Journal of Immunology. 189 , p. 5037-5046 10 p.
Patients with unstable angina pectoris show an increased frequency of the Fc gamma RIIa R131 allele.
Raaz-Schrauder D., Ekici A.B., Munoz L.E., Klinghammer L., Voll R.E., Leusen J.H.W., van de Winkel J.G.J., Reis A., Schett G., Garlichs C.D., Herrmann M. 2012, In: Autoimmunity. 45 , p. 556-564 9 p.
Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages.
Lohse S., Brunke C., Derer S., Peipp M., Boross P., Kellner C., Beyer T., Dechant M., van de Winkel J.G.J., Leusen J.H.W., Valerius T. 2012, In: Journal of Biological Chemistry. 287 , p. 25139-25150 12 p.
Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity.
Kellner C., Hallack D., Glorius P., Staudinger M., Mohseni Nodehi S., de Weers M., van de Winkel J.G.J., Parren P.W.H.I., Stauch M., Valerius T., Repp R., Humpe A., Gramatzki M., Peipp M. 2012, In: Leukemia. 26 , p. 830-834 5 p.
Enhanced FcαRI-mediated neutrophil migration towards tumour colonies in the presence of endothelial cells.
Otten M.A., Bakema J.E., Tuk C.W., Glennie M.J., Tutt A.L., Beelen R.H., van de Winkel J.G.J., van Egmond M. 2012, In: European Journal of Immunology. 42 , p. 1815-1821 7 p.